Rituxin treatment
is not included in this comparison because not enough patients took
this treatment at the time data was entered into the data base
Response Times in Years
|
Treatment |
Number of
patients |
Average response time |
Median Response time |
Patients No other
treatment |
Average response
time ongoing |
Median response
time ongoing |
Patients
requiring 2nd series |
Average
response1st series for patients requiring 2nd series |
Median
response1st series for patients requiring 2nd
series |
|
2CdA |
72 |
1.89 |
1.74 |
43 |
2.03 |
1.94 |
29 |
1.79 |
1.08 |
|
Fludarabine |
62 |
1.68 |
1.48 |
45 |
1.78 |
1.52 |
17 |
1.41 |
1.00 |
|
Chlorambucil |
156 |
2.16 |
1.42 |
63 |
2.50 |
1.58 |
93 |
1.92 |
1.25 |
|
Cytoxan |
41 |
2.48 |
2.08 |
22 |
2.41 |
2.08 |
19 |
2.55 |
2.08 |
|
Treatment |
Number of
patients taking a
combination of the treatment |
Average response Time combination of
the treatment |
Median Response Time combination of
the treatment |
|
2CdA |
13 |
1.83 |
1.97 |
|
Fludarabine |
20 |
1.34 |
0.93 |
|
Chlorambucil |
48 |
1.62 |
1.00 |
|
Cytoxan |
29 |
1.95 |
1.55 |
|
Treatment |
Average age |
Median |
Age range |
Number of
patients |
|
2CdA |
59.6 |
59.1 |
35 to 78 |
72 |
|
Fludarabine |
59.7 |
60.9 |
35 to 81 |
62 |
|
Chlorambucil |
61.2 |
61.5 |
34 to 81 |
156 |
|
Cytoxan |
58 |
59.8 |
32 to 77 |
41 |
|
Treatment |
Average IgM 6 month reduction |
Median IgM 6 month reduction |
Average WBC 6 month reduction |
Median WBC 6 month reduction |
Average RBC 6 month increase |
Median RBC 6 month increase |
Average HGB 6 month increase |
Median HGB 6 month increase |
|
2CdA |
2000 |
1500 |
0.9 |
0.9 |
0.4 |
0.0 |
1.7 |
2.5 |
|
Fludarabine |
2481 |
2250 |
1.4 |
1.5 |
0.2 |
0.0 |
2.1 |
1.9 |
|
Chlorambucil |
1464 |
2450 |
0.9 |
0.5 |
0.1 |
0.0 |
0.8 |
0.5 |
|
Cytoxan |
2140 |
1500 |
0.9 |
0.5 |
0.1 |
0.0 |
2.0 |
2.0 |